Improving cardiovascular health outcomes through the use of evidence-based medicine

Ethnicity and Disease

Volumn 15, Issue 2 SUPPL. 2, 2005, Pages

  Douglas, Janice ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

AASK; ALLHAT; CKD; Hypertension; JNC 7; LIFE; Metabolic syndrome; Proteinuria; VALUE

Indexed keywords

EID: 61849174314     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
2. Expert Panel on Detection, Evaluation, and Treatment ol High Blood Cholesterol. JAMA. 2001;285:2486-2497.
3. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004; 140:167-174.
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypettension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
5. Staessen JA, Fagatd R, Thijs L, et al, for the Systolic Hypertension in Europe Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997:350:757-764.
6. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients high cardiovascular risk treated with regimens based on valsattan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022-2031.
7. Hasson L, Lindholm EH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Capropril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611-616.
8. Hasson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751-1756.
9. Hasson L, Hedner T, Luud-Johansen P, et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359-365.
10. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocket ot diutetic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000,356:366-372.
11. ALLHAT officers and cootdinatots fot the ALLHAT Collabotative Research Gtoup. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypettensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002:288:2981-2997.
12. Black HR, Elliott WJ, Grandits G, et al. Principal results of the controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073-2082.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
14. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting enzyme inhibitor therapy in Black as compared with White patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
15. Dries DL, Strong MH, Cooper RS, et al Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventticulat dysfunction to symptomatic heart failure in Black and White patients. J Am Coll Cardiol. 2002;40:311-317.
16. Wtight JT, Baktis G, Gteene T, et al. Effect ot blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results of the AASK trial. JAMA. 2002;288:2421-2431.
17. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87.
18. Miettinen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke or other atherogenic vascular disease events in non-diabetic and non-insulin dependent diabetic subjects. Stroke. 1996;27:2039.
19. Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35:898-903.
20. Wright JT, Rahman M, Scarpa A, et al. Determinants of salt sensitivity in Black and White normotensive and hypertensive women. Hypertension. 2003;42:1087-1092.